News
Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts. Export articles to Mendeley Get article recommendations from ACS based on references in your ...
First-in-class antibody-drug conjugate, pivekimab sunirine (PVEK), was safe and effective. PVEK achieved an overall response rate of 85% and complete response rate of 70% as frontline treatment in ...
The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm ...
EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. It is currently undergoing Phase 1 clinical trials for ...
adm.cgmh.org.tw In 500 children aged ≤10 years after 13-valent pneumococcal conjugate vaccine (PCV)13 immunisation in different schedules, serotypes 19A-specific and 19F-specific immunoglobulin G (IgG ...
antibody-drug conjugate (ADC), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). ZL-1310, which is being evaluated in an ongoing global Phase 1a/1b clinical trial (NCT06179069 ...
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer - The Company is on track to initiate ...
‡ The Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing 100084, People’s Republic of China § College ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results